RESUMO
OBJECTIVES: The use of heparin-coated circuits for cardiopulmonary bypass attenuates the postperfusion inflammatory response. Postoperative bleeding and the need for allogeneic blood transfusions are reduced, particularly in combination with lowered systemic anticoagulation. The two most commonly used heparin-coated systems are the Carmeda BioActive Surface (Medtronic Inc, Minneapolis, Minn) and the Duraflo II coating (Baxter Healthcare Corp, Bentley Laboratories Division, Irvine, Calif). The 2 surfaces are technically unequal, and previous experimental studies have demonstrated disparities in effects on the immune system and the blood cells. However, no larger comparative studies of relevant clinical end points have thus far been reported. METHODS: Over a 24-month period, all patients undergoing coronary artery bypass were prospectively randomized to one of the two heparin-coated circuits. Altogether, 1336 consecutive patients were included. The heparin dose was reduced in all cases, with an activated coagulation time of more than 250 seconds. Clinical data were consecutively collected and stored on a computer for comparative analyses. RESULTS: There were no statistically significant differences in any demographic or operative parameters. The Duraflo II patients required less heparin to keep the target-activated clotting time, confirming the previous finding of some leakage of heparin from the surface to the circulation. Otherwise, there were no significant differences in time for ventilatory support (Duraflo II, 1.7 +/- 1.3 hours; Carmeda BioActive Surface, 1.6 +/- 1.0 hours; P =.37), amount of postoperative mediastinal drainage (Duraflo II, 665 +/- 257 mL; Carmeda BioActive Surface, 688 +/- 243 mL; P =.07), need for allogeneic blood-plasma transfusions (Duraflo II, 4.2% of the patients; Carmeda BioActive Surface, 4.4% of the patients; P =.93), or hemoglobin concentration at hospital discharge (Duraflo II, 120 +/- 13 g/L; Carmeda BioActive Surface, 119 +/- 13 g/L; P =.08). The effects on renal function and platelets were similar, as were the incidences of perioperative myocardial infarction (Duraflo II, 1.5%; Carmeda BioActive Surface, 1.5%; P =.96), stroke (Duraflo II, 1.3%; Carmeda BioActive Surface, 1.2%; P =.47), and hospital mortality (Duraflo II, 1 [0.14%] patient; Carmeda BioActive Surface, 3 [0.45%] patients; P =.31). CONCLUSIONS: Despite differences in technology, complexity, and effects on biologic markers, no clinical differences were observed between the Carmeda BioActive Surface system and the Duraflo II coating after coronary artery bypass operations. The overall clinical results were favorable in both groups, confirming the safety and feasibility of routine use of heparin-coated circuits in combination with reduced systemic anticoagulation.
Assuntos
Anticoagulantes , Ponte Cardiopulmonar/instrumentação , Materiais Revestidos Biocompatíveis , Fibrinolíticos , Heparina , Anticoagulantes/administração & dosagem , Coagulação Sanguínea , Feminino , Fibrinolíticos/administração & dosagem , Heparina/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de TempoRESUMO
The contribution of fibrinolysis to postoperative bleeding after cardiopulmonary bypass led to routine use of tranexamic acid, a potent antifibrinolytic drug, for a period of time. Two hundred patients undergoing elective coronary artery bypass operations were studied, one group of 100 patients given tranexamic acid (40 mg/kg) (group I) after bypass and one subsequent group of 100 patients (group II) serving as a control group. All patients were treated by the same team, and the groups were comparable in all major clinical parameters. The mean mediastinal drainage in group I was 565 +/- 239 ml versus 656 +/- 257 ml in group II. Univariate and multivariate analysis revealed statistical significance (p = 0.02) when corrected for body surface area. However, applying a consistent blood conservation protocol, including removal of autologous blood before bypass for retransfusion after bypass, returning of all oxygenator and tubing contents to the patients, and autotransfusion of the mediastinal shed blood up to 18 hours postoperatively, resulted in nearly identical hemoglobin concentration at discharge (119 +/- 14 gm/L in group I and 121 +/- 14 gm/L in group II). The prevalence of postoperative myocardial infarction included five patients in group I compared with one patient in group II. Although not statistically significant (p = 0.2), the difference is of concern. Tranexamic acid has a beneficial effect on reducing postoperative bleeding after coronary artery bypass operations. The routine use of the drug is not recommended, however, because its effect is a weak one, and it may be of potential hazard by precipitating thrombosis and eventual myocardial infarction.
Assuntos
Ponte de Artéria Coronária/efeitos adversos , Hemorragia/tratamento farmacológico , Complicações Pós-Operatórias/tratamento farmacológico , Ácido Tranexâmico/uso terapêutico , Adulto , Idoso , Transfusão de Sangue Autóloga , Superfície Corporal , Deambulação Precoce , Feminino , Hematócrito , Hemoglobinas/análise , Hemorragia/sangue , Hemorragia/epidemiologia , Hospitais Especializados , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Infarto do Miocárdio/complicações , Infarto do Miocárdio/epidemiologia , Noruega/epidemiologia , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/epidemiologia , Prevalência , Estudos Prospectivos , Estudos Retrospectivos , Fatores de Risco , Volume Sistólico , Ácido Tranexâmico/administração & dosagemRESUMO
OBJECTIVE: Autotransfusion during and after cardiac surgery is widely performed, but its effects on coagulation, fibrinolysis, and inflammatory response have not been known in detail. METHODS: Hemostatic and inflammatory markers were extensively studied in 40 coronary artery bypass patients undergoing a consistent intraoperative and postoperative autotransfusion protocol. An identical autotransfusion protocol was applied to 4916 consecutive coronary patients and the overall clinical results were evaluated in this large patient population. RESULTS: The autologous blood pooled before bypass remained nearly inactivated after storage. A slight elevation of thrombin-antithrombin complex and prothrombin fragment 1.2, as well as plasmin/alpha(2)-antiplasmin complex was found in the content of the extracorporeal circuit after surgery, indicating thrombin formation and fibrinolytic activity. Also some increase of beta-thromboglobulin was present. In the mediastinal shed blood, complete coagulation, as evidenced by the absence of fibrinogen, had taken place and all parameters described above were extremely elevated. However, no thrombin activity was detected. As for the inflammatory response, moderately increased levels of complement activation products, terminal complement complex, and interleukin-6 traced in the extracorporeal circuit reached very high levels in mediastinal shed blood. Autotransfusion of the residual extracorporeal circuit blood and the mediastinal drainage was followed by elevation of most of these markers in circulating plasma. On the other hand, no correlating harmful effects were recorded in the study patients or in the consecutive 4916 patients. Coagulation disturbances were rare and allogeneic transfusions were required in fewer than 4% of all patients. CONCLUSIONS: The hemostatic and immunologic systems were moderately activated in the autologous blood remaining in the extracorporeal circuit, whereas the mediastinal shed blood was highly activated in all aspects. However, autotransfusion had no correlating clinical side-effects and the subsequent exposure to allogeneic blood products was minimal.
Assuntos
Antifibrinolíticos , Transfusão de Sangue Autóloga , Ponte de Artéria Coronária , Idoso , Antitrombina III/análise , Biomarcadores/sangue , Coagulação Sanguínea/fisiologia , Ponte Cardiopulmonar , Ativação do Complemento , Complexo de Ataque à Membrana do Sistema Complemento/análise , Drenagem , Feminino , Fibrinogênio/análise , Fibrinolisina/análise , Fibrinólise/fisiologia , Hemostasia/fisiologia , Humanos , Interleucina-6/sangue , Cuidados Intraoperatórios , Modelos Lineares , Masculino , Mediastino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/análise , Peptídeo Hidrolases/análise , Cuidados Pós-Operatórios , Protrombina/análise , Síndrome de Resposta Inflamatória Sistêmica/etiologia , Trombina/biossíntese , alfa 2-Antiplasmina/análise , beta-Tromboglobulina/análiseRESUMO
Complement and granulocyte activation were studied in cardiopulmonary bypass circuits completely coated with either end-attached covalent-bonded heparin, the Carmeda BioActive Surface, or with the Duraflo II bonded heparin, in combination with reduced systemic heparinization (activated clotting time > 250 seconds). The control groups were perfused with uncoated circuits and full heparin dose (activated clotting time > 480 seconds). Altogether 67 patients undergoing elective first-time myocardial revascularization were investigated, having extracorporeal perfusion with a Duraflo II coated circuit (n = 17), an identical but uncoated circuit (n = 17), a Carmeda coated circuit (n = 17), or an equivalent uncoated circuit (n = 16). During cardiopulmonary bypass, the C3 activation products C3b, iC3b, and C3c (C3bc) and the terminal SC5b-9 complemented complex increased markedly in all four groups compared with baseline, but significantly less in the two coated groups than in their control groups. Additionally, a significantly lower concentration of C3bc was observed in the Carmeda coated group, with maximal increase of median 28 AU/ml compared with 50 AU/ml in the Duraflo II coated group (p = 0.003). Similarly, in the Carmeda coated group, the maximal increase of terminal complement complex was considerably lower (0.8 AU/ml) than the levels recognized in the Duraflo II coated group (2.4 AU/ml) (p < 0.001). The release of the granulocyte activation myeloperoxidase and lactoferrin increased from the beginning of the operation, with peak levels at the end of bypass. A significant reduction of lactoferrin release was recognized when comparing the coated groups with the control groups. The difference between the two coated groups (Carmeda 228 micrograms/L; Duraflo II 332 micrograms/L; p = 0.05) was marginally significant. For myeloperoxidase, no significant differences were observed between the coated and uncoated groups. In conclusion, both types of heparin-coated circuits reduced complement activation and release of lactoferrin, but the Carmeda circuit proved to be more effective than the Duraflo II equipment.
Assuntos
Ponte Cardiopulmonar/instrumentação , Ativação do Complemento , Ponte de Artéria Coronária , Granulócitos/imunologia , Heparina , Idoso , Ponte Cardiopulmonar/efeitos adversos , Complemento C3/análise , Complexo de Ataque à Membrana do Sistema Complemento/análise , Procedimentos Cirúrgicos Eletivos , Feminino , Heparina/administração & dosagem , Humanos , Lactoferrina/sangue , Masculino , Pessoa de Meia-Idade , Peroxidase/sangue , Propriedades de SuperfícieRESUMO
BACKGROUND: Increasing hospital costs, restricted resources, and new surgical strategies have stimulated effectiveness of all routines in cardiac surgery. Over a 10-year period, 5,658 consecutive patients undergoing coronary artery bypass grafting followed a protocol aiming at short postoperative intubation times and rapid physical rehabilitation. METHODS: The patients were prepared for rapid recovery, emphasizing (1) preoperative education and respiratory training, (2) low-dose fentanyl anesthesia, (3) limited ischemic times and pump times, (4) mild hypothermia and rewarming to a rectal temperature of 36 degrees C, (5) restricted use of extended monitoring, (6) autologous blood salvage to avoid allogeneic blood transfusions, and (7) active physical training from postoperative day 1. All in-hospital data relevant to these steps were prospectively stored in a database. RESULTS: The median extubation time after arrival in the intensive care unit was 1.5 hours (0 to 320 hours). More than 99% of the patients were extubated within 5 hours. Sixty-two patients (1.1%) were reintubated and ventilated for a median of 24 hours (1 to 430 hours), mostly due to resternotomy for bleeding or cardiopulmonary decompensation. In total, 5,594 patients (98.9%) were able to sit in a chair the first postoperative day. Within the fourth postoperative day, 82.5% were able to move freely in the hospital area and were in fact physically fit for hospital discharge. Allogeneic blood products were given to 3.9% of the patients. Twenty-three patients (0.41%) died in-hospital. CONCLUSIONS: With the application of a protocol for rapid physical recovery in patients undergoing "on-pump" coronary artery bypass grafting, extubation within 1 to 2 hours was safe and feasible in most patients. After 5 hours, 99.3% of the patients were extubated, with a reintubation rate of 1.1%. More than 80% of the patients were fully physically mobile within 4 days after the operation.
Assuntos
Ponte Cardiopulmonar/reabilitação , Ponte de Artéria Coronária/reabilitação , Complicações Pós-Operatórias/reabilitação , Adulto , Idoso , Idoso de 80 Anos ou mais , Ponte Cardiopulmonar/mortalidade , Ponte de Artéria Coronária/mortalidade , Deambulação Precoce , Feminino , Mortalidade Hospitalar , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/mortalidade , Estudos Prospectivos , Análise de SobrevidaRESUMO
BACKGROUND: The concepts of minimally invasive coronary artery bypass grafting have gained increasing attention and interest from cardiac surgeons. Operations through small incisions are mostly applied to patients with less extensive coronary disease, mostly single-vessel disease. The aim of this study was to identify a baseline level of conventional coronary bypass grafting for this group of patients, particularly with regard to surgical complications and immediate results. METHODS: Of 3,637 consecutive patients undergoing coronary artery bypass grafting during the period 1989 to 1995, 99 patients (2.7%) were identified to have single-vessel disease. The preoperative and hospital data of this subset of patients were analyzed. RESULTS: The left internal mammary artery was grafted in 96% of the patients, either as single graft to the left anterior descending artery or sequentially to the left anterior descending artery and a diagonal branch. Additional vein grafts were placed in 36 patients, and the mean number of distal anastomoses was 1.6 +/- 0.6. Mean ischemic time and cardiopulmonary bypass time were 15.3 +/- 9.6 minutes and 29.0 +/- 12.5 minutes, respectively. The patients were weaned from the ventilator 1.5 +/- 0.8 hours postoperatively, and all patients were out of bed the morning after the operation. No patients required homologous blood or plasma transfusions. The morbidity rate was low, and all patients survived. CONCLUSIONS: For this highly selected group of patients, coronary artery bypass grafting based on median sternotomy, cardiopulmonary bypass, and cardioplegic arrest carries a very high rate of immediate success. Such data may be useful as a baseline when considering the costs and benefits of new surgical procedures.
Assuntos
Ponte de Artéria Coronária , Doença das Coronárias/cirurgia , Ponte Cardiopulmonar , Ponte de Artéria Coronária/métodos , Feminino , Parada Cardíaca Induzida , Humanos , Anastomose de Artéria Torácica Interna-Coronária , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos , Valores de Referência , Veia Safena/transplante , Esterno/cirurgiaRESUMO
With use of a nonpharmacological, simple, and inexpensive program for blood conservation, 500 consecutive patients underwent elective coronary artery bypass grafting without need of homologous red cell transfusions in 493 (98.6%). At least one internal mammary artery was grafted in all but 1 patient, with supplemental saphenous vein grafts. Intraoperatively, autologous heparinized blood was removed before bypass and retransfused at the conclusion of extracorporeal circulation. The volume remaining in the oxygenator and tubing set was returned without cell processing or hemofiltration. Using the hard-shell cardiotomy reservoir from the heart-lung machine, autotransfusion of the shed mediastinal blood was continued hourly up to 18 hours after operation. The mean postoperative mediastinal blood loss was 643 +/- 354 mL, whereas 624 +/- 296 mL was autotransfused. Thirteen patients (2.6%) needed reexploration for bleeding, of whom 7 (7/500, 1.4%) received homologous blood. No other patients required red cell transfusions. In addition, 9 patients were given a mean of 2.6 units of fresh frozen plasma because of suspected coagulopathy. No platelets were transfused, and no cryoprecipitate therapy was undertaken. Thus, in total, 484 patients (96.8%) were not exposed to any homologous blood products during the hospital stay. At discharge, the mean hemoglobin concentration was 121 +/- 14 g/L (12.1 +/- 1.4 g/dL) and the hematocrit, 0.36 +/- 0.04. Postoperative complications were few. There was one in-hospital death (0.2%).
Assuntos
Preservação de Sangue/métodos , Ponte de Artéria Coronária , Adulto , Idoso , Transfusão de Sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-OperatóriasRESUMO
BACKGROUND: The use of completely heparin coated cardiopulmonary bypass circuits in combination with a reduced systemic heparin dose has previously been shown to reduce postoperative bleeding after cardiac operations. However, it has remained unknown whether this effect was related to the improved biocompatibility of the heparin-treated surfaces per se or to the reduced exposure to circulating heparin. Therefore we investigated patients undergoing heparin-coated extracorporeal circulation and full systemic heparinization. METHODS: Two hundred seventeen patients having first-time myocardial revascularization were prospectively randomized either to a group in which a completely ("tip-to-tip") heparin-coated circuit (Duraflo II) was used for perfusion (n = 107) or to a control group (n = 110) in which an uncoated, but otherwise identical, circuit was used. Full systemic heparinization was induced in both groups (activated clotting time, > 480 seconds). The postoperative blood loss, requirements for homologous blood transfusions, clinical performance, and complications were recorded. RESULTS: The amount of postoperative mediastinal drainage was nearly identical in the two groups. The mean 18-hour drainage was 694 +/- 313 mL in the heparin-coated group and 679 +/- 269 mL in the control group (p = not significant). Three patients in the heparin-coated group and 6 patients in the control group received homologous red blood cell transfusions (p = not significant). The incidence of postoperative atrial fibrillation was significantly lower in the heparin-coated group (21.8%) than in the control group (43.1%) (p = 0.002). Otherwise, there were no significant differences in the extubation times, the incidence of perioperative myocardial infarction, the creatinine concentration, the incidence of neurologic dysfunction, the progress in physical rehabilitation, or the hemoglobin concentration at discharge. CONCLUSIONS: The use of completely heparin coated cardiopulmonary bypass circuits and full systemic heparinization in patients undergoing coronary artery bypass procedures did not reduce postoperative bleeding or change clinical performance, except for a significant decrease in the incidence of postoperative atrial fibrillation.
Assuntos
Ponte Cardiopulmonar , Heparina/administração & dosagem , Arritmias Cardíacas/etiologia , Transfusão de Sangue , Ponte de Artéria Coronária , Drenagem , Feminino , Humanos , Masculino , Mediastino , Pessoa de Meia-Idade , Cuidados Pós-Operatórios , Complicações Pós-Operatórias , Hemorragia Pós-Operatória/prevenção & controle , Estudos ProspectivosRESUMO
BACKGROUND: Ventricular fibrillation after declamping of the aorta after cardioplegic arrest is commonly managed by direct-current countershock. However, in coronary artery bypass grafting, placement of the electrodes can cause mechanical damage to the grafts and anastomoses, and the surgical procedure must be interrupted. As an alternative, intraaortic infusion of potassium chloride through the arterial line from the heart-lung machine was investigated. METHODS: In a series of 100 patients with postischemic ventricular fibrillation (group P), 20 mmol of potassium chloride (plus 10 mmol later if necessary) was added to the oxygenator reservoir and perfused through the arterial line into the proximal aorta. The results were compared with those in a matched control group of 100 patients primarily treated with direct-current countershock (group DC). RESULTS: In group P, the ventricular fibrillation was effectively converted to a supraventricular rhythm in 82% of the patients. The remaining 18 patients required significantly (p < 0.005) fewer electric shocks than the patients in group DC. Serum K+ levels were slightly elevated for a short period after the potassium chloride infusion. Otherwise there were no significant differences in regard to incidence of heart block, temporary epicardial pacing, myocardial infarction, or atrial fibrillation between the two groups. CONCLUSIONS: Conversion of postischemic ventricular fibrillation with potassium chloride administered through the arterial line from the heart-lung machine is an effective, gentle, and convenient method. No side effects were noted.
Assuntos
Infusões Intra-Arteriais , Cloreto de Potássio/uso terapêutico , Fibrilação Ventricular/tratamento farmacológico , Adulto , Idoso , Estudos de Casos e Controles , Cardioversão Elétrica , Feminino , Parada Cardíaca Induzida/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Cloreto de Potássio/administração & dosagem , Estudos Retrospectivos , Resultado do Tratamento , Fibrilação Ventricular/etiologia , Fibrilação Ventricular/terapiaRESUMO
BACKGROUND: The activated clotting time is a bedside method routinely used to monitor heparin anticoagulation during operations requiring cardiopulmonary bypass. The thrombolytic assessment system heparin management test is a new bedside method for monitoring heparin effect. We compared these methods with respect to their ability to reflect the actual heparin concentration in plasma determined by an anti-FXa method. METHODS: Two studies were done, an ex vivo study on ten patients who had coronary artery bypass using non-heparin-coated cardiopulmonary bypass circuits and full systemic heparinization and an in vitro study on single donor plasma spiked with heparin 0 to 10 IU/mL. RESULTS: Ex vivo study correlation coefficients of activated clotting time and the thrombolytic assessment system heparin management test clotting times versus anti-FXa-based heparin assay were low (r = 0.53, p = 0.002/r = 0.64, p<0.001) in contrast with the corresponding correlation coefficients for the in vitro study (r = 0.98, p<0.001/r = 0.99, p<0.001). A substantial variability in duplicate activated clotting time determinations was noted, which was less pronounced with the thrombolytic assessment system heparin management test. CONCLUSIONS: The thrombolytic assessment system method does not correlate better to the actual amount of heparin during cardiopulmonary bypass procedures than the activated clotting time method, which should be performed in duplicate.
Assuntos
Anticoagulantes/administração & dosagem , Testes de Coagulação Sanguínea/métodos , Ponte de Artéria Coronária , Heparina/administração & dosagem , Anticoagulantes/sangue , Ponte Cardiopulmonar , Heparina/sangue , HumanosRESUMO
BACKGROUND: Cardiopulmonary bypass with heparin-coated circuits allows reduced amounts of systemic heparin. Heparin inhibits activation of the complement cascade experimentally, but the effects of different levels of systemic heparin on activation of complement and granulocytes in patients have remained unknown. METHODS: Fifty-two patients undergoing coronary artery bypass procedures were studied. Cardiopulmonary bypass circuits completely coated with surface-bound heparin were used for one group given low-dose heparin (n = 17) (activated clotting time > 250 seconds), and was compared with a second group having normal high-dose heparin (activated clotting time > 480 seconds) (n = 18). A third control group was perfused with ordinary uncoated circuits and a full heparin dose (n = 17). RESULTS: During cardiopulmonary bypass, the C3 activation products C3b, iC3b, and C3c increased markedly in all three groups compared with baseline, but significantly less in the two heparin-coated groups (high dose, median maximal increase 58 arbitrary units (AU)/mL; low dose, 48 AU/mL) compared with the uncoated control group (74 AU/mL) (p < 0.01). The difference between the two coated groups was not significant. Similarly, the maximal increase in terminal SC5b-9 complement complex was considerably lower in the heparin-coated groups (high dose, 2.5 AU/mL; low dose, 2.6 AU/mL) compared with the level observed in the uncoated control group (5.3 AU/mL) (p < 0.01). The release of the granulocyte activation enzymes myeloperoxidase and lactoferrin increased from the beginning of the operation, with peak levels at the end of cardiopulmonary bypass (p < 0.01). The concentration of lactoferrin was significantly (p < 0.01) reduced in the low heparin dose group compared with the two other groups receiving normal high heparin doses, indicating that circulating heparin is an important granulocyte agonist, acting independently of the presence or absence of heparin-coated surfaces. Also for myeloperoxidase a higher level was observed in the high heparin dose group. CONCLUSIONS: Complement activation was significantly reduced in both heparin-coated groups and was independent of the level of systemic heparinization, whereas granulocyte activation was reduced only in patients who received low doses of systemically administered heparin. The results indicate that a moderate reduction of the systemic heparin dose may be an advantage with regard to improved biocompatibility when using heparin-coated cardiopulmonary bypass circuits.
Assuntos
Anticoagulantes/administração & dosagem , Ponte Cardiopulmonar , Ativação do Complemento/efeitos dos fármacos , Granulócitos/fisiologia , Heparina/administração & dosagem , Adulto , Idoso , Anticoagulantes/farmacologia , Complemento C3/metabolismo , Complexo de Ataque à Membrana do Sistema Complemento/análise , Proteínas do Sistema Complemento/análise , Ponte de Artéria Coronária , Feminino , Glicoproteínas/análise , Heparina/farmacologia , Humanos , Lactoferrina/sangue , Masculino , Pessoa de Meia-Idade , Peroxidase/sangueRESUMO
BACKGROUND: When heparinized circuits are used for cardiopulmonary bypass, the amounts of heparin and protamine administered systemically can be reduced. However, it is not entirely known what effects this reduction in systemic anticoagulation has on clinical performance and on the coagulation and fibrinolytic systems. METHODS: Two hundred three patients undergoing first-time elective myocardial revascularization were prospectively randomized either to a group in which a completely heparin-coated circuit was used for perfusion (group H; n = 101 patients) and in which a reduced heparin dose was given (activated clotting time, > 250 seconds) or to a control group (group C; n = 102 patients) in which an uncoated, but otherwise identical, circuit was used and in which full systemic heparinization was induced (activated clotting time, > 480 seconds). Indicators of thrombin generation, platelet activation, and fibrinolytic activity were studied in a subset of 34 patients. RESULTS: The total amount of postoperative mediastinal drainage was significantly reduced in group H (median, 575 mL) compared with that in group C (median, 635 mL; p = 0.002). Two patients in group C but none in group H received homologous red blood cell transfusions (p = not significant). The loss of hemoglobin in group H was a median of 21 g/L, and this was significantly lower than the 25 g/L noted in the control group (p = 0.006). During cardiopulmonary bypass, the plasma levels of thrombin-antithrombin complex and prothrombin fragment 1.2 increased in both groups. At the end of cardiopulmonary bypass the plasma levels of these markers of thrombin formation were significantly higher in group H, although the increase was modest compared with the major increase observed 2 hours after operation in both groups. There were no significant intergroup differences in the platelet counts, the concentration of beta-thromboglobulin, or the plasma levels of fibrinogen and D-dimer. No differences in perioperative morbidity, the postoperative kidney function, or the intubation time were observed, and there were no hospital deaths. CONCLUSIONS: The combination of complete heparin-coated cardiopulmonary bypass circuits and low systemic heparinization is safe for patients undergoing elective coronary artery bypass procedures and reduces the perioperative blood loss. There was no evidence of increased thrombogenicity, fibrinolytic activity, or consumption of coagulation factors. No clinical or technical side effects were observed.
Assuntos
Ponte Cardiopulmonar/métodos , Hemostasia Cirúrgica/métodos , Heparina/administração & dosagem , Adulto , Idoso , Antitrombina III/análise , Perda Sanguínea Cirúrgica/prevenção & controle , Ponte Cardiopulmonar/instrumentação , Procedimentos Cirúrgicos Eletivos , Feminino , Fibrinólise , Hemostasia , Humanos , Masculino , Pessoa de Meia-Idade , Revascularização Miocárdica , Peptídeo Hidrolases/análise , Estudos Prospectivos , Protaminas/administração & dosagemRESUMO
Twelve patients with refractory myocardial failure following open heart surgery were treated with a temporary left (10), right (1) or biventricular (1) assist circuits driven by extracorporeal pumps. Ten of 11 patients were weaned from the pump oxygenator. During left ventricular assist, maximal pump flow was 2.2 +/- 0.6 l/min per m2 at a cardiac index of 2.5 +/- 0.9 l/min per m2. Diuresis was above 1 ml/kg body weight per h in 7 of 9 patients perfused for 13-36 h. Seven patients were weaned from the assist pump after 13-33 h of ventricular bypass with 4 hospital survivors. Two patients died after circulatory assistance of multiple organ failure, 1 from cerebral damage. In the other patients, the main problems were cardiac. Three patients are currently long term survivors 12-17 months after surgery.
Assuntos
Ponte de Artéria Coronária/efeitos adversos , Coração Auxiliar , Ponte Cardiopulmonar , Ponte de Artéria Coronária/mortalidade , Feminino , Humanos , Complicações Intraoperatórias/mortalidade , Complicações Intraoperatórias/terapia , Masculino , Pessoa de Meia-Idade , Fatores de TempoRESUMO
Because much interest has been focused on blood conservation using different drugs and complicated blood cell processing devices, we analyzed our results with the use of a non-pharmacologic, simple and inexpensive program for blood salvage in 2326 patients undergoing myocardial revascularization. The material was divided into two groups: patients undergoing a primary coronary bypass operation (Group P, n = 2298) and a smaller subset of patients undergoing repeat coronary bypass operation (Group R, n = 28). At least one internal mammary artery was grafted in 99% of the patients, with supplemental saphenous vein grafts. Intraoperatively, autologous heparinized blood was removed before bypass and retransfused at the conclusion of extracorporeal circulation. The volume remaining in the extracorporeal circuit was returned without cell processing or hemofiltration. Autotransfusion of the shed mediastinal blood was continued hourly up to 18 h after surgery in all patients. The mean postoperative mediastinal drainage in group R was 543 +/- 218 ml, compared to 703 +/- 340 ml in Group P (P = 0.01). In Group R, 1 patient (3.6%) received packed red cells and no patients were given other homologous blood products, compared to 33 patients (1.4%) given red cells and 35 patients (1.5%) given plasma transfusion in Group P (NS). Thus, in total, 2257 patients (97.0%) were not exposed to any homologous blood products during hospitalization. Total hemoglobin loss was significantly higher in Group R, resulting in a mean hemoglobin concentration at discharge of 109 +/- 13 g/l, compared to 121 +/- 14 g/l in Group P (P = 0.0002).(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Perda Sanguínea Cirúrgica/prevenção & controle , Preservação de Sangue , Transfusão de Sangue Autóloga , Ponte de Artéria Coronária/métodos , Transfusão de Eritrócitos , Hemoglobinas/análise , Troca Plasmática , Idoso , Volume Sanguíneo , Drenagem , Feminino , Humanos , Cuidados Intraoperatórios , Masculino , Pessoa de Meia-Idade , Cuidados Pós-Operatórios , Reoperação , Resultado do TratamentoRESUMO
A 60-year-old male patient developed progressive wound ulcerations, simulating wound sepsis after coronary bypass operation. The condition did not respond to intensive antibiotic therapy. Based on clinical signs and biopsy, the diagnosis of pyoderma gangrenosum was made and successfully treated with cyclosporin A. Pyoderma gangrenosum, although extremely rare, must be considered as a possible diagnosis in wound complications unresponsive to traditional therapy.
Assuntos
Angina Pectoris/cirurgia , Ponte de Artéria Coronária , Pioderma Gangrenoso/diagnóstico , Infecção da Ferida Cirúrgica/diagnóstico , Biópsia , Ciclosporina/uso terapêutico , Diagnóstico Diferencial , Humanos , Masculino , Pessoa de Meia-Idade , Pioderma Gangrenoso/tratamento farmacológico , Pioderma Gangrenoso/patologia , Veia Safena/transplante , Esterno/patologia , Esterno/cirurgia , Infecção da Ferida Cirúrgica/tratamento farmacológico , Infecção da Ferida Cirúrgica/patologia , Cicatrização/efeitos dos fármacosRESUMO
Restriction of donor blood transfusions in cardiac surgery should decrease the risk of infective contamination and antigenicity. Following a simple, systematic and inexpensive blood conservation program, we report on 250 consecutive patients undergoing elective coronary artery bypass surgery, 247 (98.6%) of whom did not need homologous blood transfusions. At least one internal mammary artery was grafted in all but one patient, in combination with saphenous vein grafts. Intraoperatively, autologous heparinized blood was removed before bypass and retransfused at the conclusion of extracorporeal circulation. The remaining volume of the oxygenator and tubing set was retransfused without any cell processing or hemofiltration. Using the hard-shell cardiotomy reservoir from the heart lung machine, autotransfusion of the shed mediastinal blood was continued hourly up to 18 h after surgery. The mean postoperative mediastinal bleeding was 622 +/- 287 ml, of which 589 +/- 296 ml was autotransfused. Five patients (2.0%) needed re-exploration for bleeding, and three of these received 1-4 units of homologous blood. No other patients needed red cell transfusions. Seven patients were given a mean of 2.6 units of fresh frozen plasma because of coagulopathy. Thus, altogether 240 patients (96%) were not exposed to any homologous blood products during their hospital stay. Morbidity was low. At discharge, the mean hemoglobin concentration was 12.0 +/- 1.4 g/dl and the mean hematocrit 36.0 +/- 4.2%. There were no deaths.
Assuntos
Transfusão de Sangue , Ponte de Artéria Coronária , Adulto , Idoso , Perda Sanguínea Cirúrgica , Transfusão de Sangue Autóloga , Feminino , Humanos , Complicações Intraoperatórias , Masculino , Pessoa de Meia-Idade , Complicações Pós-OperatóriasRESUMO
OBJECTIVE: Heparin-coated extracorporeal circuits allow reduced amounts of systemic heparin and protamine. However, the effects on the coagulation and fibrinolytic systems when reducing systemic anticoagulation, have partly remained unknown. METHODS: Thirty-three patients undergoing elective first time myocardial revascularization were prospectively randomized either to have a cardiopulmonary bypass (CPB) circuit completely coated with covalently bound heparin, in combination with reduced systemic heparinization (activated clotting time (ACT) > 250 s (n = 17), or to a control group perfused with identical but uncoated circuits and full heparin dose (ACT > 480 s) (n = 16). Tests indicative of thrombin generation, platelet activation, and fibrinolytic activity were performed intraoperatively and postoperatively. RESULTS: During CPB, the plasma level of prothrombin fragment 1.2 (PF 1.2) increased from median 1.5 (1.1-1.9) nmol/l to 5.4 (3.3-6.6) nmol/l in the heparin-coated group, and was significantly higher (P = 0.01) than the increase from 1.4 (1.2-1.9) nmol/l to 3.2 (2.2-4.3) nmol/l seen in the control group. However, the increase on CPB was modest compared to the major elevation observed after completed surgery and reversal of the anticoagulation. The concentrations reached median 9.7 (6.8-19.5) nmol/l in the heparin-coated group and 13.2 (4.2-18.4) nmol/l in the control group (no significant intergroup difference). A similar pattern was observed for the thrombin-antithrombin (TAT) complex. Regression analysis revealed significant correlation between the levels of the thrombin markers and duration of CPB in both groups (P < 0.05). There was no correlation between ACT or plasma heparin levels on bypass and the PF 1.2 and TAT complex. The platelet release of beta-thromboglobulin increased in both groups during CPB and significantly more in the control group at the end of bypass (P < 0.01), indicating less platelet activation in the heparin-coated group. There were no significant intergroup differences with regard to fibrinolytic activity. Plasma fibrinogen as well as platelet counts were unchanged after the operation, compared to baseline. Except for one patient in the control group sustaining perioperative myocardial infarction, the postoperative course was uneventful in all cases. CONCLUSIONS: Completely heparin-coated CPB can safely be performed in combination with reduced systemic heparinization. The heparin and protamine amounts could be lowered to 35% of normal doses. Indications of more thrombin generation on CPB compared to the uncoated controls were seen, but the levels remained within low ranges in both groups. There was no evidence of thromboembolic episodes or clot formation in the extracorporeal circuits.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Ponte Cardiopulmonar/instrumentação , Fibrinólise/efeitos dos fármacos , Heparina , Revascularização Miocárdica , Adulto , Idoso , Coagulação Sanguínea/fisiologia , Desenho de Equipamento , Feminino , Fibrinólise/fisiologia , Heparina/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Ativação Plaquetária/efeitos dos fármacos , Ativação Plaquetária/fisiologia , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/tratamento farmacológico , Propriedades de Superfície , Trombina/metabolismo , Tempo de Coagulação do Sangue TotalRESUMO
Complete heparin-coated extracorporeal circuits, including cardiotomy reservoir, have recently become available for routine cardiac surgery. The effects on complement and granulocyte activation using a heparin-coated circuit in combination with reduced systemic heparinization (activated clotting time (ACT) > 250 s) were studied in 33 patients undergoing elective first time myocardial revascularization. The patients were prospectively randomized either to a heparin-coated group (Group H, n = 17), or to a control group (Group C, n = 16) treated with an identical uncoated circuit and full heparin dose (ACT > 480 s). During cardiopulmonary bypass (CPB) the C3 activation products C3b, iC3b, and C3c (C3bc) and the terminal SC5b-9 complement complex (TCC) increased markedly in both groups compared to baseline, but to a much lesser extent in the heparin-coated group. The maximal increase of C3bc during the operation was a median of 28 arbitrary units (AU)/ml in the heparin-coated group, compared to 45 AU/ml in the control group (P = 0.01). Similarly, in Group H the maximal increase of TCC was significantly lower (median 0.8 AU/ml) than the levels recognized in Group C (median 1.9 AU/ml) (P < 0.0001). The release of the granulocyte activation enzymes lactoferrin and myeloperoxidase also increased during CPB in both groups compared to baseline level. The maximal increase of lactoferrin concentration was a median of 229 micrograms/l in Group H and significantly lower than 647 micrograms/l in the control group (P = 0.0002). As for myeloperoxidase, there were no significant intergroup differences. In conclusion, a complete heparin-coated circuit and low systemic heparinization for CPB in coronary artery surgery were associated with reduced activation of the complement system and less release of lactoferrin. The results indicate improved biocompatibility of this option for extracorporeal circulation.